Marian Plunkett

US Patent:

7517855, Apr 14, 2009

Filed:

Nov 25, 2003

Appl. No.:

10/723144

Inventors:

Robert J. Ternansky - San Diego CA, US
Stephanie A. Hopkins - Poway CA, US
Won Hyung Yoon - San Diego CA, US
Amy L. Allan - Encinitas CA, US
Patricia L. Gladstone - San Diego CA, US
Sean M. O'Hare - San Diego CA, US
Fernando Donate - San Diego CA, US
Andrew Mazar - San Diego CA, US
Graham Parry - San Diego CA, US
Marian Plunkett - San Diego CA, US

Assignee:

Attenuon, LLC - San Diego CA

International Classification:

A61K 38/00
A61K 38/14
C07K 5/00
C07K 7/00
C07K 16/00
C07K 17/00
C07K 9/00

US Classification:

514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 530324, 530325, 530326, 530327, 530328, 530329, 530330, 530331

Abstract:

The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

US Patent:

20030082740, May 1, 2003

Filed:

Feb 14, 2002

Appl. No.:

10/074225

Inventors:

Fernando Donate - San Diego CA, US
Scott Harris - San Diego CA, US
Marian Plunkett - San Diego CA, US
Andrew Mazar - San Diego CA, US

International Classification:

C12N009/99
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/069200, 435/184000, 435/320100, 435/325000, 536/023200

Abstract:

Histidine Proline Rich Glycoprotein (HPRG) polypeptides or fragments thereof including pentapeptide fragments and multimers thereof, and other biologically active derivatives of HPRG are anti-angiogenic. These compounds may be used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic. These compounds therefore have anti-tumor activity and are used in methods for inhibiting the growth of primary tumors or metastases. Antibodies specific for epitopes of the His-Pro rich domain of HPRG are stimulators of angiogenesis and are useful for promoting neovascularization in pertinent disease states.